214 related articles for article (PubMed ID: 31729458)
1. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor.
Takeshita T; Yan L; Asaoka M; Rashid O; Takabe K
Sci Rep; 2019 Nov; 9(1):16942. PubMed ID: 31729458
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
3. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
[TBL] [Abstract][Full Text] [Related]
4. ATP2C2 Has Potential to Define Tumor Microenvironment in Breast Cancer.
Liu J; Wei Y; Wu Y; Li J; Sun J; Ren G; Li H
Front Immunol; 2021; 12():657950. PubMed ID: 33936088
[TBL] [Abstract][Full Text] [Related]
5. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
8. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer.
Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
[TBL] [Abstract][Full Text] [Related]
10. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer.
Mony JT; Schuchert MJ
Front Immunol; 2018; 9():2298. PubMed ID: 30374348
[No Abstract] [Full Text] [Related]
12. Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.
Chabab G; Barjon C; Abdellaoui N; Salvador-Prince L; Dejou C; Michaud HA; Boissière-Michot F; Lopez-Crapez E; Jacot W; Pourquier D; Bonnefoy N; Lafont V
J Leukoc Biol; 2020 Jun; 107(6):1057-1067. PubMed ID: 32362028
[TBL] [Abstract][Full Text] [Related]
13. Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Nagahashi M; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933189
[TBL] [Abstract][Full Text] [Related]
14. Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial.
Stenmark Tullberg A; Puttonen HAJ; Sjöström M; Holmberg E; Chang SL; Feng FY; Speers C; Pierce LJ; Lundstedt D; Killander F; Niméus E; Kovács A; Karlsson P
Clin Cancer Res; 2021 Feb; 27(3):749-758. PubMed ID: 33148672
[TBL] [Abstract][Full Text] [Related]
15. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Leivonen SK; Pollari M; Brück O; Pellinen T; Autio M; Karjalainen-Lindsberg ML; Mannisto S; Kellokumpu-Lehtinen PL; Kallioniemi O; Mustjoki S; Leppä S
Haematologica; 2019 Feb; 104(2):338-346. PubMed ID: 30237271
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
17. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
Burugu S; Asleh-Aburaya K; Nielsen TO
Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
[TBL] [Abstract][Full Text] [Related]
18. Distribution and prognostic value of tumor‑infiltrating T cells in breast cancer.
Meng S; Li L; Zhou M; Jiang W; Niu H; Yang K
Mol Med Rep; 2018 Nov; 18(5):4247-4258. PubMed ID: 30221739
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
[TBL] [Abstract][Full Text] [Related]
20. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
